Publication | Closed Access

HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma

Breast OncologyMedicinePathologyAnti-her2 Neoadjuvant ChemotherapyBreast CancerCancer TreatmentIncomplete ResponseOncologyRadiation OncologyHer2 Intratumoral HeterogeneityTumor Biology